Saturday 17 October 2026
Export APYX’s income statement to Excel — free account
Apyx Medical Corporation
APYX Healthcare Medical Devices
Apyx Medical Corporation’s revenue for fiscal 2025 (year ended December 2025) was $52.8 million, up 9.86% from fiscal 2024. In the quarter to June 2026, revenue grew 22.1%, EPS grew 22.2%, free cash flow fell 137.4% and total debt rose 2.74%, each against the same quarter a year earlier.
2.55
0.01
−0.39%
Follow APYX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
1.82 | 2.72 | 2.89 | 3.37 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(24.66) | (56.85) | (282.18) | (56.41) | |
P/B ratio |
14.34 | 9.70 | 12.33 | 17.75 | |
Price to Tangible BV |
14.79 | 9.82 | 12.51 | 18.05 | |
EV/Sales |
2.20 | 2.95 | 3.12 | 3.65 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(12.56) | (19.48) | (22.14) | (21.08) | |
EV/FCF |
(11.12) | (17.10) | (19.38) | (19.32) | |
Quick Ratio |
3.47 | 4.15 | 4.65 | 4.41 | |
Current Ratio |
4.44 | 5.00 | 5.80 | 5.68 | |
Net Debt/EBITDA |
(14.21) | 13.45 | (5.58) | (4.79) | |
Debt/Assets |
60.36% | 52.16% | 55.68% | 57.85% | |
Debt/Equity |
5.69 | 2.35 | 2.68 | 3.19 | |
Asset Turnover |
0.81 | 0.80 | 0.91 | 0.98 | |
Operating CF/Net income |
1.78 | 1.95 | 0.27 | 1.08 | |
Capex/Depreciation |
(3.16) | (1.24) | (0.30) | (0.34) | |
Interest Coverage |
(0.59) | 0.01 | (0.67) | (1.30) | |
Research and Development Expense of Revenue |
6.22% | 4.93% | 6.12% | 5.71% | |
Selling, General and Administrative Expense of Revenue |
64.67% | 57.63% | 64.62% | 71.18% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
4.12% | 2.61% | 2.50% | 7.74% | |
Graham Net Nets |
(0.03) | 0.04 | 0.03 | 0.02 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(16.82%) | (7.71%) | (5.96%) | (4.45%) | |
Free Cash Flow Yield |
(10.89%) | (6.34%) | (5.57%) | (5.61%) | |
Revenue per Share |
0.32 | 0.47 | 0.29 | 0.32 | |
Operating CF per Share |
(0.09) | (0.06) | (0.01) | (0.08) | |
Capex per Share |
(0.01) | (0.01) | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.10) | (0.07) | (0.01) | (0.08) | |
Cash per Share |
0.62 | 0.77 | 0.71 | 0.63 | |
Shareholders Equity per Share |
0.15 | 0.36 | 0.30 | 0.25 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.15 | 0.36 | 0.30 | 0.25 | |
Free Cash Flow |
(4.05) | (2.80) | (0.63) | (3.56) | |
Working Capital |
37.81 | 46.77 | 45.35 | 43.80 | |
Capital Expenditures |
(0.52) | (0.27) | (0.06) | (0.07) | |
Net Current Asset Value |
(2.50) | 6.46 | 4.86 | 3.17 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.04 | 0.01 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
13.02 | 16.13 | 12.20 | 12.43 | |
Average Payables |
2.57 | 2.84 | 2.47 | 2.54 | |
Average Inventory |
9.07 | 8.08 | 8.61 | 9.47 | |
Average Assets |
59.04 | 65.84 | 61.59 | 59.63 | |
Average Common Equity |
8.64 | 14.58 | 11.87 | 9.27 |
Columns are period end dates